← Eichor
Condition: Specific Advanced Solid Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Specific Advanced Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 33 location(s) · CStone Pharmaceuticals · NCT06741644A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shine-On Biomedical Co., Ltd. · NCT07055594Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07648069TCR-T Cell Therapy on Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05438667FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07638371Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Immunotherapy for the Treatment of Advanced Solid Tumor
Phase 1/Phase 2 · 1 location(s) · Tongji Hospital · NCT03658785Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT00900471HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
Phase 1 · 1 location(s) · Shanghai Ruiliyuan Biotechnology Co., Ltd. · NCT06515314Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Phase 1 · 1 location(s) · Sichuan University · NCT06084286Personalized Neoantigen Peptide Vaccines for Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Seqker Biosciences, Inc. · NCT07002203Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 25 location(s) · AstraZeneca · NCT06005493Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · 21 location(s) · Revolution Medicines, Inc. · NCT05379985A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan
Phase 1/Phase 2 · 7 location(s) · Merck Sharp & Dohme LLC · NCT07302347First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Phase 1 · 10 location(s) · EpimAb Biotherapeutics (Suzhou)Co., Ltd. · NCT05607498High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) D
NA · 1 location(s) · Medical College of Wisconsin · NCT05301101A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06612840Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · Guangzhou FineImmune Biotechnology Co., LTD. · NCT03891706First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
Phase 1/Phase 2 · 5 location(s) · VelaVigo Bio Inc · NCT07136779Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03740256GTB-5550 in Advanced Solid Tumors
Phase 1 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07541573NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Phase N/A · 1 location(s) · Bayer · NCT04945330A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Eisbach Bio GmbH · NCT06525298PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate
Phase 2/Phase 3 · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07426094A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specifi
Phase 1 · 10 location(s) · Bayer · NCT06659341Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Phase 1 · 15 location(s) · Acrivon Therapeutics · NCT06667141Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 2 · 1 location(s) · Guangzhou JOYO Pharma Co., Ltd · NCT06895031TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumo
Phase 2 · 181 location(s) · American Society of Clinical Oncology · NCT02693535PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostat
Phase 2/Phase 3 · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07426055
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.